A new self-rating scale for detecting atypical or second-generation antipsychotic side effects.
about
Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-AnalysisComparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study.Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.A cluster randomised controlled trial and process evaluation of a training programme for mental health professionals to enhance user involvement in care planning in service users with severe mental health issues (EQUIP): study protocol for a randomiLay health supporters aided by a mobile phone messaging system to improve care of villagers with schizophrenia in Liuyang, China: protocol for a randomised control trialSMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects.Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons.Monitoring and documentation of side effects from depot antipsychotic medication: an interdisciplinary audit of practice in a regional mental health service."First do no harm." A systematic review of the prevalence and management of antipsychotic adverse effects.Screening for incontinence in a secure psychiatric service for women.Rating scales to measure side effects of antipsychotic medication: A systematic review.Antipsychotic medication side effect assessment tools: A systematic review.Academic detailing among psychiatrists - feasibility and acceptability.Survey of antipsychotic medication curriculum content in Australian university nursing programmes.A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting.Efficacy and Tolerability of Clozapine versus Quetiapine in Treatment-resistant Schizophrenia.Acceptability and tolerability of omega-3 fatty acids as adjunctive treatment for children and adolescents with eating disorders.Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial.What side effects are problematic for patients prescribed antipsychotic medication? The Maudsley Side Effects (MSE) measure for antipsychotic medication.Australian mental health nurses' perspectives about the identification and management of antipsychotic medication side effects: a cross-sectional survey.Mental health nurses' views about antipsychotic medication side effects.The use of Enhancing Quality Use of Medication Self-Reported Questionniare (EQUIM-SRQ) among mental health consumers: a pilot study.A Mobile Health Platform for Clinical Monitoring in Early Psychosis: Implementation in Community-Based Outpatient Early Psychosis Care.Patterns of Prescription of Psychotropic Medications and Their Adherence among Patients with Schizophrenia in Two Psychiatric Hospitals in Accra, Ghana: A Cross-Sectional Survey.Translation and cultural adaptation of Glasgow Antipsychotic Side-effects Scale (GASS) in ArabicEmbedding shared decision-making in the care of patients with severe and enduring mental health problems: The EQUIP pragmatic cluster randomised trial
P2860
Q26748476-3A2BBA72-A926-4438-B86D-70C51B8CEF99Q33568876-13AE0075-70C6-4865-B3A6-13B18EEB24B8Q33857710-6E5DB084-BE68-414B-A8E7-A8AE85EF0DEBQ35949973-35E34846-A2F8-4A97-96FF-174E7BBC84BAQ36526847-1BA43FC1-B101-43E1-8964-B039C138CE2AQ37495004-B2689026-4EDC-414E-8BE9-AB6EBF1298EFQ37953186-913D1B01-C546-473C-ACA3-FC4FDFE33FD0Q37954453-4E31C6CF-B0A1-41C0-BB85-EB9FA12C1B95Q38291338-6736F2F4-422B-46B6-903A-040F19309810Q38543073-DFCC4C5F-4F7B-4134-94F3-46B14D0287FFQ38544223-8D84CC2B-76CF-4950-B5C3-E3CE91B44746Q38611031-028A5638-AC5D-470A-BCDF-D82D94724FCFQ39010717-18A2F3E4-553D-438E-951A-07538A73FBA4Q39159979-0B0C28F5-1593-456B-A597-F331D05C59F6Q43271104-95729E5E-4784-4818-B43B-85C1BE403062Q47101612-898198AA-1A05-4D2B-9527-778B9798755AQ47364469-6CE331DE-EDC1-4365-A561-719C57A4BC56Q47565684-9A7CC1FC-9E2C-4B94-B05B-C46A78B72212Q47745528-21515A39-4F19-44A6-8E61-AEB4D8051E85Q47924691-0760F409-CA6B-402C-B4F1-D279386E8351Q47992912-A64481F1-9BA2-4101-9F0F-279B09C53904Q50748895-BE655477-B640-43F6-BFBF-81A159ADE85EQ51150812-12500EE4-7D0D-4C59-9251-16B67D59F9F2Q53434932-AFD91490-0EE9-4DC6-A9E8-FE01EBD64321Q58715936-F305DB88-2246-4345-A706-047EC10B1D20Q58723642-C691FA67-204D-4B0F-9055-C5CBA2B3327A
P2860
A new self-rating scale for detecting atypical or second-generation antipsychotic side effects.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A new self-rating scale for de ...... on antipsychotic side effects.
@en
A new self-rating scale for de ...... on antipsychotic side effects.
@nl
type
label
A new self-rating scale for de ...... on antipsychotic side effects.
@en
A new self-rating scale for de ...... on antipsychotic side effects.
@nl
prefLabel
A new self-rating scale for de ...... on antipsychotic side effects.
@en
A new self-rating scale for de ...... on antipsychotic side effects.
@nl
P2860
P356
P1476
A new self-rating scale for de ...... on antipsychotic side effects.
@en
P2093
P2860
P304
P356
10.1177/0269881107087976
P407
P577
2008-05-01T00:00:00Z